A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer

Annals of Oncology

Volumn 20, Issue 7, 2009, Pages 1178-1184

  Colleoni, Marco ^a   Bagnardi, V ^a,b,c   Rotmensz, N ^a   Dellapasqua, S ^a   Viale, G ^d   Pruneri, G ^d   Veronesi, P ^a   Torrisi, R ^a   Luini, A ^a   Intra, M ^a   Galimberti, V ^a   Montagna, E ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Frontier Science and Technology Research Foundation   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Disease free survival; Nomogram; Predictive factors; Preoperative chemotherapy; Primary therapy

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL TIME;

EID: 67650382242     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn747     Document Type: Article

References (33)

1. Powles TJ, Hickish TF, Makris A et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-552.
2. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
3. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
4. Colleoni M, Minchella I, Mazzarol G et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000; 11: 1-3.
5. MacGrogan G, Mauriac L, Durand M et al. Primary chemo-therapy in breast invasive carcinoma: P(odictive value of the immuno-histochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996; 74: 1458-1465.
6. Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the-use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003; 21: 2600-2608.
7. Rouzier R, Pusztai L, Delaloge S et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2004; 22: 2294-2302.
8. Chollet P, AmatS, Belembaogo E et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 2003; 89: 1185-1191.
9. Abrial SC, Penault-Llorca F, Delva R et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer. Breast Cancer. Res Treat 2005; 94: 255-263.
10. Kuerer HM, Newman LA, Smith TM et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
11. Harrell FE. A Cee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
12. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526.
13. Harrell FE Jr. Design and Hmisc libraries. http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/RS (last accessed on 1 October 2008).
14. Rouzier R, Extra JM, Klijanienko J et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20: 1304-1310.
15. Scholl SM, Pierga JY, Asselain B et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995; 31: 1969-1975.
16. Regan MM, Viale G, Mastropasqua MG et al. Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. JNCI Cancer Spectr 2006; 98: 1571-1581.
17. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
18. Goldhirsch A, Wood WC, Senn HJ et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87: 1441-1445.
19. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
20. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
21. Thomas E, Holmes FA, Smith TL et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004; 22: 2294-2302.
22. Goldhirsch A, Wood WC, Gelber RD. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
23. Curé H, Amat S, Penault-Llorca F et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat 2002; 76: 37-45.
24. Lee AK, DeLellis RA, Silverman ML et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990; 8: 1457-1465.
25. Lauria R, Perrone F, Carlomagno C et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995; 76: 1772-1778.
26. Montagna E, Bagnardi V, Rotmensz N et al. Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer 2008; 98: 1745-1752.
27. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
28. Gregory RK, Powles TJ, Salter J et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 2000; 59: 171-175.
29. Domagala W, Markiewski M, Harezga B et al. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein. Clin Cancer Res 1996; 2: 147-154.
30. Mandard AM, Denoux Y, Herlin P et al. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: Multivariate analysis with Ki-67 index, mitotic count, and microvessel density. Cancer 2000; 89: 1748-1757.
31. de Azambuja E, Cardoso F, de Castro G Jr et al. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 1504-1513.
32. Archer CD, Parton M, Smith IE et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003; 89: 1035-1041.
33. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100: 1380-1388.